'Steps in place to monitor drug trials'

Image
BS Reporter New Delhi
Last Updated : May 10 2012 | 12:27 AM IST

Under attack over the functioning of the Central Drugs Standard Control Organisation (CDSCO), the Ministry of Health and Family Welfare today claimed to have “already taken several steps” to plug the loopholes in the system.

Reacting to a standing committee report on the functioning of CDSCO, tabled in Parliament yesterday, the ministry said it was examining the observations. “After receipt of inputs from CDSCO on the report and thorough its scrutiny, appropriate action would be taken by the ministry wherever required,” the statement said.

The ministry had already “initiated several steps to strengthen the CDSCO and streamline its functioning”, it added.

The committee, headed by Brajesh Pathak of the Samajwadi Party, said 31 new drugs were approved from January 2008 to October 2010 without conducting clinical trials on Indian patients. “Thus, there is no scientific evidence to show these 33 drugs are really effective and safe in Indian patients.”

On why new drugs were being approved without clinical trials, ministry officials had given “public interest” as their reply to the committee. The ministry stated the Drugs and Cosmetic Rules did not prescribe specific situations, under which clinical trial exemption could be granted due to public interest.

The panel also pointed out that most of the ills in the system of drug regulation in India were mainly due to CDSCO’s “skewed priorities and perceptions”. For decades, the organisation had been facilitating drugs industry, due to which the interest of the biggest stakeholder — consumer — has never been ensured.

The panel has also raised concern over CDSCO being severely under-staffed and the long duration of time taken to complete recruitment. Of the 327 sanctioned posts, only 124 are occupied.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 10 2012 | 12:27 AM IST

Next Story